Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05632354 · ClinicalTrials.gov registry record · Phase 2
GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05632354: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT05632354 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 47 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05632354, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. Serious adverse events (SAEs) were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other
Interventions
- DRUG Osivelotor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-01-05 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 2 |
Why NCT05632354 stopped before completion
NCT05632354 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Osivelotor is the first listed.
NCT05632354 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05632354 about?
NCT05632354 is a clinical study titled "GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)". An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
What is the current status of trial NCT05632354?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2023-01-05. Estimated completion is 2025-02-13.
What interventions are being tested in trial NCT05632354?
The interventions under investigation include: Osivelotor (DRUG).
Who is sponsoring clinical trial NCT05632354?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05632354's enrollment target sits among peer trials
47 1283rd of 2000 higher than 715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI